Galera Therapeutics, Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 36338D108 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Ikarian Capital, LLC 13G/A Amendment 1	0%	0	13G/A Amendment 1	8/14/2026 Event 6/30/2026
Ikarian Capital, LLC	0%	0
Neil Shahrestani	0%	0
Parvinder Singh Hyare 13D	6.7%	13,521,921	13D	6/11/2026 Event 5/15/2026
Emerald Bioventures, LLC 13D/A Amendment 1	30.2%	61,029,978	13D/A Amendment 1	5/29/2026 Event 5/15/2026
Emerald Bioventures, LLC	30.2%	61,029,978
Timothy Opler	30.2%	61,029,978
Emerald Bioventures, LLC 13D	26.5%	40,216,160	13D	4/27/2026 Event 4/7/2026
Emerald Bioventures, LLC	26.5%	40,216,160
Timothy Opler	26.5%	40,216,160
Chang Nancy T 13D	5.9%	8,921,543	13D	4/10/2026 Event 12/30/2024
Ikarian Capital, LLC 13G	10.0%	7,538,690	13G	2/14/2025 Event 12/31/2024
Ikarian Capital, LLC	10.0%	7,538,690
Neil Shahrestani	10.0%	7,538,690

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q1	1	93.0	$4.00	$0
2024 Q2	1	52.1 k	$7.13 k	$0
2024 Q1	41	9.79 M	$1.37 M	$1.44 k
2023 Q4	41	12.9 M	$1.88 M	$320.00
2023 Q3	41	8.77 M	$1.53 M	$2.22 k
2023 Q2	63	18.5 M	$57.8 M	$8.21 M
2023 Q1	46	18.7 M	$54.4 M	$7.05 M
2022 Q4	37	12.0 M	$17.9 M	$73.8 k
2022 Q3	36	10.4 M	$18.1 M	$265 k
2022 Q2	45	10.5 M	$13.7 M	$284 k
2022 Q1	56	11.3 M	$26.9 M	$1.66 M
2021 Q4	56	11.2 M	$51.3 M	$6.53 M
2021 Q3	41	20.0 M	$162 M	$0
2021 Q2	49	20.8 M	$204 M	$0
2021 Q1	56	19.4 M	$171 M	$0
2020 Q4	52	19.3 M	$197 M	$0
2020 Q3	45	18.8 M	$170 M	$0
2020 Q2	42	18.7 M	$134 M	$0
2020 Q1	36	16.9 M	$160 M	$0
2019 Q4	34	17.0 M	$224 M	$0